|
|
Press Releases
| All Releases |
|---|
 |
Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months
Nov 13, 2009
|
14.2 KB
|
| |
SAN DIEGO, Calif., Nov 13, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) announced today that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its Priority Review of the New Drug Application (NDA) for intravenous (IV) acetaminophen...
|
|
|
Cadence Pharmaceuticals Reports Third Quarter 2009 Financial Results
Nov 5, 2009
|
17.8 KB
|
| |
SAN DIEGO, Nov 05, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today reported financial results for the three and nine months ended S...
|
|
|
Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2009 Financial Results on November 5, 2009
Oct 29, 2009
|
9.5 KB
|
| |
SAN DIEGO, Oct 29, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it will release its third quarter ended September...
|
|
|
Cadence Pharmaceuticals' CEO Ted Schroeder To Present at the Oppenheimer 20th Annual Healthcare Conference in New York City on November 4, 2009
Oct 28, 2009
|
9.3 KB
|
| |
SAN DIEGO, Oct 28, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Ted Schroeder wil...
|
|
|
Cadence Pharmaceuticals' CEO Ted Schroeder to Present at the BIOCOM Investor Conference in San Diego on October 27, 2009
Oct 20, 2009
|
9.3 KB
|
| |
SAN DIEGO, Oct 20, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Ted Schroeder wil...
|
|
|
Cadence Pharmaceuticals to Webcast October 7th Analyst Day
Sep 30, 2009
|
13.4 KB
|
| |
SAN DIEGO, Sept 30, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that it will host a live webcast of its Analyst Day o...
|
|
|
Cadence Pharmaceuticals' CEO Ted Schroeder to Present at the JMP Securities Healthcare Focus Conference in New York on October 6, 2009
Sep 29, 2009
|
9.3 KB
|
| |
SAN DIEGO, Sept 29, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Ted Schroeder wi...
|
|
|
Cadence Pharmaceuticals to Present at Two Investment Conferences During the Month of September 2009
Sep 9, 2009
|
9.7 KB
|
| |
SAN DIEGO, Sept 09, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company will be presenting at the following ...
|
|
|
Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results
Aug 5, 2009
|
17.5 KB
|
| |
SAN DIEGO, Aug 05, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today reported financial results for the three and six months ended Ju...
|
|
|
Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the Canaccord Adams Global Growth Conference in Boston on August 11, 2009
Aug 4, 2009
|
9.1 KB
|
| |
SAN DIEGO, Aug 04, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Theodore Schroede...
|
|
|
Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2009 Financial Results on August 5, 2009
Jul 29, 2009
|
9.3 KB
|
| |
SAN DIEGO, July 29, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it will release its second quarter ended June 30...
|
|
|
Cadence Pharmaceuticals Announces Priority Review and Acceptance of NDA Submission for Acetavance(TM) for Treatment of Acute Pain and Fever
Jul 15, 2009
|
13.4 KB
|
| |
SAN DIEGO, July 15, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) announced today that its New Drug Application (NDA) for Acetavance(TM) (intravenous acetaminophen), its investigational product candidate for the treatment of acute pain and fever in adults and children, has been accepted for fil...
|
|
|
Cadence Pharmaceuticals Announces Appointment of Scott Byrd as Chief Commercial Officer
Jun 22, 2009
|
12.1 KB
|
| |
SAN DIEGO, June 22, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) announced today that Scott Byrd has joined the company as Senior Vice President and Chief Commercial Officer. Mr. Byrd will report directly to Ted Schroeder, President and Chief Executive Officer, and his responsibilities will in...
|
|
|
Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the Needham Life Sciences Conference in New York on June 11, 2009
Jun 4, 2009
|
9.8 KB
|
| |
SAN DIEGO, June 4, 2009 /PRNewswire via COMTEX News Network/ -- SAN DIEGO, June 4 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's P...
|
|
|
Cadence Pharmaceuticals Submits Acetavance New Drug Application for the Treatment of Acute Pain and Fever
May 14, 2009
|
13.9 KB
|
| |
SAN DIEGO, May 14, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational product candidate, Acetavance(TM) (intravenous acetaminophen), for the treatment of acute pai...
|
|
|
Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results
May 7, 2009
|
16.1 KB
|
| |
SAN DIEGO, May 7, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today reported financial results for the first quarter ended March 31, ...
|
|
|
Cadence Pharmaceuticals' CEO Ted Schroeder to Present at Two Investment Conferences During the Month of May 2009
May 5, 2009
|
10.0 KB
|
| |
SAN DIEGO, May 5, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Theodore Schroeder...
|
|
|
Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2009 Financial Results on May 7, 2009
Apr 30, 2009
|
9.6 KB
|
| |
SAN DIEGO, April 30, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it will release its first quarter ended March 3...
|
|
|
Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
Apr 27, 2009
|
10.6 KB
|
| |
SAN DIEGO, April 27, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) announced today that data from clinical trials of its investigational product candidate, Acetavance(TM) (intravenous acetaminophen), will be presented at the American Society of Regional Anesthesia and Pain Medicine (ASRA) 34th A...
|
|
|
Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference in New York on April 2, 2009
Mar 26, 2009
|
9.8 KB
|
| |
SAN DIEGO, March 26, 2009 /PRNewswire via COMTEX News Network/ -- SAN DIEGO, March 26 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company...
|
|
|
|
| Stock Quote |
CADX - (NASDAQ)
$10.34
+ 0.45
Feb 9, 2010
3:59 PM ET |
Quotes delayed at
least 20 minutes.
Information provided
by eSignal.
|
